Esclerosis sistémica inducida por paclitaxel

  1. González-Vázquez, Laura 1
  2. Cobas-Paz, Ana 2
  3. Valle-Feijóo, Luisa 1
  4. Senín-Estor, Clara 3
  5. de la Fuente-Aguado, Javier 1
  1. 1 Servicio de Medicina Interna. Hospital Povisa. Vigo (Pontevedra). España
  2. 2 Servicio de Neumología. Hospital Povisa. Vigo (Pontevedra). España
  3. 3 Servicio de Oncología. Hospital Povisa. Vigo (Pontevedra). España
Journal:
Revista Española de Casos Clínicos en Medicina Interna (RECCMI)

ISSN: 2530-0792

Year of publication: 2018

Issue Title: Spanish Journal of Case Records in Internal Medicine

Volume: 3

Issue: 2

Pages: 52-55

Type: Article

DOI: 10.32818/RECCMI.A3N2A3 DIALNET GOOGLE SCHOLAR lock_openOpen access editor

More publications in: Revista Española de Casos Clínicos en Medicina Interna (RECCMI)

Sustainable development goals

Abstract

Taxanes are effective antineoplastic drugs against different solid tumors. Its use has been related to the development of scleroderma like skin lesions which in some patients are accompanied by visceral involvement, Raynaud, capillary alterations and positivitation of antibodies. We present the case of a patient who, after receiving paclitaxel for an ovarian neoplasia, develops a systemic scleroderma with rapidly evolving interstitial pulmonary involvement.

Bibliographic References

  • Van den Hoogen F, Khanna D, Fransen J, et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum. 2013; 65: 2737-2747.
  • Bielopolski D, Evron E, Moreh-Rahav O, et al. Paclitaxel induced pneumonitis in patients with breast cancer: case series and review of the literature. J Chemother. 2017; 29(2): 113-117.
  • Holmes FA, Walters RS, Theriault BHL, et al. Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst. 1991; 83: 1797-1805.
  • Sibaud V, Leboeuf NR, Roche H, et al. Dermatological adverse events with taxane chemotherapy. Eur J Dermatol. 2016; 26: 427-443.
  • Battafarano DF, Zimmerman GC, Older SA, et al. Docetaxel (taxotere) associated scleroderma like changes of the lower extremities. A report of three cases. Cancer. 1995; 76: 110-115.
  • Läuchli S, Trüeb RM, Fehr, et al. Scleroderma like drug reaction to paclitaxel (Taxol®). Br J Dermatol. 2002; 147: 619-621.
  • Takahashi T, Asano Y, Ichimura Y, et al. A case of taxane induced scleroderma: a different expression profile of Fli1 proteins in dermal fibroblasts and microvascular endothelial cells compared with systemic sclerosis. Br J Der- matol. 2011; 164: 1393-1395.
  • Kowal-Bielecka O, Fransen J, Avouac J, et al. Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis. 2017; 76: 1327-1339.
  • Tashkin DP, Roth MD, Clements PJ, et al. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma related intesrttial disease (SLS-II): a randomised controlled, double blind, parallel group trial. Lancet Respir Med. 2016; 4: 708-719.
  • Clevelan MG, Ajaikumar BS, Reganti R. Cutaneous fibrosis induced by doce taxel. Cancer. 2000; 88: 1078-1081.
  • Hassett G, Harnett P, Manolios N. Scleroderma in association with the use of docetaxel (taxotere) for breast cáncer. Clin Exp Rheumatol. 2001; 19: 197- 200.
  • De Angelis R, Bugatti L, Cerioni A, et al. Diffuse scleroderma occurring after the use of paclitaxel for ovarian cancer. Clin Rheumatol. 2003; 22: 49-52.
  • Kupfer I, Balguerie X, Courville P, et al. Scleroderma like cutaneous lesions induced by paclitaxel: a case study. J Am Acad Dermatol. 2003; 48: 279-281.
  • Farrant PBJ, Mortimer PS, Gore M. Scleroderma and the taxanes. Is there really a link? Clin Exp Dermatol. 2004; 29: 360-362.
  • Itoh M, Yanaba K, Kobayashi T, et al. Taxane induced scleroderma. Br J Der- matol. 2007; 156: 363-367.
  • Kawakami T, Tsutsumi Y, Soma Y. Limited cutaneous systemic sclerosis induced by paclitaxel in a patient with breast cancer. Arch Dermatol. 2009; 145: 97-98.
  • Vitfell Pedersen J, Jensen S, Krarup-Hansen A, et al. Scleroderma induced by paclitaxel. Acta Oncol. 2010; 49: 866-868.
  • Kılıç MÖ, Yalaza M, Bilgiç Cİ, Dener C. Docetaxel induced scleroderma in a breast cancer patient: a case report. J Breast Health. 2015; 11: 95-97.
  • Winkelmann RR, Yiannias JA, DiCaudo DJ, et al. Paclitaxel induced diffuse cutaneous sclerosis: a case with associated esophageal dysmo- tility, Raynaud’s phenomenon, and myositis. Int J Dermatol. 2016; 55: 97-100.
  • Yang JQ, Dou TT, Chen XB, et al. Docetaxel induced scleroderma: a case report and its role in the production of extracellular matrix. Int J Rheum Dis. 2017; 20: 1835-1837.
  • Park B, Vemulapalli RC, Gupta A, et al. Docetaxel induced systemic sclerosis with internal organ involvement masquerading as congestive heart failure. Case Reports Immunol. 2017; 2017: 4249157.